Avidity biosciences enters into collaboration with fshd clinical trial network to support development of biomarkers for future clinical trial use

La jolla, calif., aug. 16, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced its collaboration with the facioscapulohumeral muscular dystrophy (fshd) clinical trial research network (fshd ctrn) to support a natural history study for people living with fshd called the motor outcomes to validate evaluations plus (move+) study.
RNA Ratings Summary
RNA Quant Ranking